Table 6

Proportion of patients achieving level 2 asthma control for each individual parameter for 95% of the treatment period (weeks 5–12) in study A1

ParameterPercentage of patients achieving control for 95% of days during weeks 5–12 (95% CI)
SFCSALMFPPL
Symptom score: day 0 or 1; night 037 (27–47)15 (8–22)29 (19–39)11 (4–18)
No exacerbations100 (100–100)95 (91–100)100 (100–100)96 (92–100)
Relief medication ≤ once daily55 (45–65)33 (23–43)34 (24–44)13 (6–20)
PEF diurnal variation ≤20%81 (73–89)46 (36–56)56 (46–67)29 (19–39)
PEF ≥80% predicted62 (52–72)21 (13–30)38 (28–48)10 (3–17)
No treatment related adverse events87 (80–94)93 (88–98)92 (86–98)98 (95–101)
  • 95% CI: 95% confidence interval; PEF: peak expiratory flow; SFC: salmeterol/fluticasone propionate combination product; SALM: salmeterol; FP: fluticasone propionate; PL: placebo. Data from ref 9, where approximately 70% of patients were previously taking inhaled corticosteroids.